26
|
Schmitt M, Harbeck N, Foekens J, Maier S. DNA-methylation markers and YB-1 as indicators of therapy response in breast cancer. EJC Suppl 2006. [DOI: 10.1016/j.ejcsup.2006.04.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
27
|
Sieuwerts A, Look M, Gelder MMV, Timmermans M, Portengen H, Klijn J, Foekens J. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node negative breast cancer patients. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80304-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
28
|
Jansen M, Sieuwerts A, Look M, Ritstier K, Gelder MMV, van Staveren I, Klijn J, Foekens J, Berns E. Expression of the HOXB13-to-IL 17BR-gene ratio in oestrogen receptor positive primary breast carcinomas: Relation with tumour aggressiveness and response to tamoxifen. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80295-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
29
|
Span P, Sweep C, Beex L, Foekens J. In Reply:. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.05.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Maier S, Nimmrich I, Marx A, Eppenberger-Castori S, Jaenicke F, Paradiso A, Spyratos F, Foekens J, Schmitt M, Harbeck N. DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.525] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Schrohl A, Holten-Andersen M, Look M, Peters H, Klijn J, Brünner N, Foekens J. 22 Total tumour tissue levels of tissue inhibitor of metalloproteinases-1 as a prognostic marker in breast cancer: an EORTC validation study of 2984 patients. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90056-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
32
|
Harbeck N, Kates R, Look M, Thomssen C, Jänicke F, Klijn J, Kiechle M, Schmitt M, Foekens J. Combination of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) has not only prognostic but also predictive impact in primary breast cancer. Breast 2003. [DOI: 10.1016/s0960-9776(03)80063-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
33
|
Klijn J, Berns E, Dorssers L, Foekens J. Predictive factors in breast cancer. Breast Cancer Res 2000. [PMCID: PMC3300890 DOI: 10.1186/bcr192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
34
|
Setyono-Han B, Foekens J, Wood J, Klijn J. Combination of antimetastatic and antiproliferative therapies in the treatment of experimental breast cancer. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80073-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Klijn J, Diamandis E, Yu H, Look M, Gelder MMV, van Putten W, Foekens J. The significance of prostate specific antigen (PSA) in breast cancer. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80440-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
36
|
Look M, Gelder MMV, Klijn J, Foekens J. PS2 helps to predict responders to tamoxifen therapy in patients with recurrent breast cancer. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80126-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Klijn J, Bems E, Look M, Meijer-van Gelder M, Foekens J. Relationship of p53, uPA, pS2, EGF-R, and c-ERBB2, with response to systemic treatment in recurrent breast cancer patient. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85576-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
|
39
|
van Roozendaal C, Klijn J, Sieuwerts A, Henzen-Logmans S, Foekens J. Role of urokinase plasminogen activator in human breast cancer: Active involvement of stromal fibroblasts. ACTA ACUST UNITED AC 1996. [DOI: 10.1016/s0268-9499(96)80056-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Klijn J, Berns P, Foekens J. SY-7-3 Growth factor receptors. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84209-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Berns P, Foekens J, de Witte H, van Putten W, Look M, Willman K, Mejervan Gelder M, Benraad T, Klijn J. PP-1-7 Accumulation of TP53 as predictor of response to chemotherapy of recurrent breast cancer. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84045-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Foekens J, Look M, Gelder MV, van Putten W, Klijn J. PP-9-4 The predictive value of the urokinase system of plasminogen activation in recurrent breast cancer. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84273-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
43
|
Klijn JG, Setyono-Han B, Bontenbal M, Seynaeve C, Foekens J. Novel endocrine therapies in breast cancer. Acta Oncol 1996; 35 Suppl 5:30-7. [PMID: 9142962 DOI: 10.3109/02841869609083965] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Endocrine therapy of breast cancer consists of a variety of both medical and surgical ablative treatment modalities, but ablative therapy is increasingly replaced by medical treatment. Most endocrine therapies have more than one endocrine effect, frequently together with direct growth inhibitory actions via receptors. Endocrine therapy can be effective in all phases of the disease, but curative only in early disease while in advanced cancer it can only prolong survival. In the past decade the number of available endocrine agents has been drastically increased. Novel approaches in the endocrine therapy of breast cancer are application of new antiestrogens, antiprogestins, new potent aromatase inhibitors, analogues of luteinizing hormone-releasing hormone (LHRH-A) and somatostatin, inhibitors of prolactin secretion, vitamin A and D analogues, bisphosphonates, growth factor antagonists, tyrosine protein kinase inhibitors, protease inhibitors, inhibitors of angiogenesis, radiolabeled hormones and monoclonal antibodies. New cell biological factors such as oncogenes and suppressorgenes, secretory proteins and membrane receptors can be used not only as prognostic factors but also for prediction of type of response to endocrine and chemotherapy. Thus, these cell biological parameters can be used to select high and low risk patients, type of systemic treatment, and can also be used as targets for new treatment modalities. Future studies on treatment of all stages of disease will increasingly focus on promising combined treatment modalities.
Collapse
|
44
|
Setyono-Han B, Foekens J, Sander H, Deckers G, Klijn J. PP-7-15 Org-OD14 significantly inhibits DMBA induced mammary tumor growth in rats: Effects of combination therapy with tamoxifen or the antiprogestin org-31710. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84232-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
Klijn J, Look M, Meijer-van Gelder M, Seynaeve C, Bontenbal M, van Geel A, Henzen-Logmans S, van Putten W, Foekens J. PP-6-2 Incidence and prognostic value of routine clinical parameters in 2273 patients with primary breast cancer treated between 1978–1990. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84185-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
46
|
van Roozendaal C, Claassen C, Klijn J, van Ooijen B, Eggermont A, Henzen-Logmans S, Foekens J. Transforming growth factor beta secretion by human breast fibroblasts in vitro. Breast 1993. [DOI: 10.1016/0960-9776(93)90150-e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
47
|
Klijn JG, Berns EM, Bontenbal M, Foekens J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 1993; 19 Suppl B:45-63. [PMID: 8481934 DOI: 10.1016/0305-7372(93)90007-e] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A large number of cell biological parameters are currently available to predict the prognosis of patients with breast cancer, but it is still difficulty accurately to predict the response to treatment. A valuable prognostic factor can be a poor predictive factor for response, and vice versa. High tumor levels of ER, PgR, AR and pS2 predict a relatively good response to endocrine therapy, while EGF-R positively, HER2/neu positivity, aneuploidy, high proliferation indices and possibly high uPA levels indicate a high chance of poor response to endocrine therapy in metastatic breast cancer. With respect to chemotherapy, a high proliferation rate and HER2/neu amplification predict a good response to therapy in metastatic disease, while MDR gene expression and possibly c-myc amplification are related to a worse response. In conclusion, the newer cell biological parameters can be used to select high and low-risk patients, type of systemic treatment, and as targets for new treatment modalities.
Collapse
|
48
|
Setyono-Han B, Bakker G, Peters H, Sieuwerts A, Eggermont A, Foekens J, Klijn J. Suramin: Pharmacokinetic monitoring, haematological and antitumor effects on rats bearing transplantable pancreatic tumors. ACTA ACUST UNITED AC 1990. [DOI: 10.1016/0277-5379(90)90443-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
Meijers M, Garderen-Hoetmer A, Foekens J, Bakker G, Klijn J, Woutersen R. Modulation of development of dietary fat-promoted (pre)neoplastic pancreatic lesions in bop-treated hamsters by (anti) hormones. ACTA ACUST UNITED AC 1990. [DOI: 10.1016/0277-5379(90)90473-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Klijn J, Setyono-Han H, Bakker G, Foekens J. Effects of somatostatin analog (SMS-A) treatment (sandostatin) in experimental and human cancer. ACTA ACUST UNITED AC 1986. [DOI: 10.1016/0277-5379(86)90217-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|